Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Avecho Biotechnology Limited ( (AU:AVE) ) has provided an update.
Avecho Biotechnology has appointed experienced corporate lawyer and company secretary Naomi Lawrie as its new Company Secretary, effective 1 May 2026, following internal team changes at its corporate services provider Vistra Australia. Lawrie, who has more than two decades of experience with health and technology companies, will oversee the company’s ASX listing rule communications, a move that supports Avecho’s governance and compliance framework as it advances late-stage clinical development of its CBD-based insomnia treatment.
More about Avecho Biotechnology Limited
Avecho Biotechnology Limited is an Australian biopharmaceutical company focused on developing and commercialising human and animal health products using its proprietary Tocopheryl Phosphate Mixture (TPM) drug delivery technology. Derived from Vitamin E through patented processes, TPM is designed to enhance the solubility and absorption of drugs and nutrients, with the company’s lead asset a CBD TPM soft-gel capsule in Phase III development for insomnia treatment.
Average Trading Volume: 7,524,185
Technical Sentiment Signal: Sell
Current Market Cap: A$44.08M
Learn more about AVE stock on TipRanks’ Stock Analysis page.